Peer-reviewedCC BY-NC-ND 4.0Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes
Abstract
The GALFLU trial showed a lower incidence of hospitalization among adults aged 65–79 years randomized to high-dose inactivated influenza vaccine (HD-IIV) vs standard-dose inactivated influenza vaccine (SD-IIV). This Bayesian re-analysis estimated >80% probability of benefit (relative vaccine effectiveness >10%) against influenza- or pneumonia-related hospitalization, supporting the benefit of HD-IIV over SD-IIV.
Clinical Trials Registration. GALFLU ClinicalTrials.gov (NCT06141655); EudraCT (2023-506977-36-00).
Related
- Pediatric Influenza Vaccine Effectiveness Against Emergency Visits and Hospitalization in Canada: 2024-2025 and 2025-2026 seasons
- Dynamics of Hospitalization and Outcomes of Patients with COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) in a Large Hospital
- Vaccine immunity can drive eosinophil recruitment in influenza breakthrough infection with mouse strain–specific outcomes
- Absolute and Relative Effectiveness of High-Dose vs Standard-Dose Influenza Vaccines Against Severe Outcomes in Older Adults
- Clinical Characteristics Associated with Mortality between Surviving and Non-surviving Adult Patients with Severe Influenza Requiring Hospitalization: An Internet-based, Prospective, Multicenter, Cohort Study in Japan
BibTeX
@article{pardoseco2026bayesian,
title = {{A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes}},
author = {Jacobo Pardo-Seco and Carmen Rodriguez-Tenreiro-Sánchez and Iago Giné-Vázquez and Narmeen Mallah and Susana Mirás-Carballal and Marta Piñeiro-Sotelo and Martín Cribeiro González and Mónica Conde Pájaro and Juan-Manuel González-Pérez and Irene Rivero-Calle and Xabier Bello and Josefina L Razzini and Antonio Salas and Rebecca C Harris and Matthew M Loiacono and Robertus van Aalst and Manel Farre and Marine Dufournet and Niklas Dyrby Johansen and Daniel Modin and Tor Biering-Sørensen and Carmen Duran-Parrondo and Federico Martinón-Torres},
journal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
year = {2026},
month = aug,
doi = {10.1093/cid/ciag466},
url = {https://doi.org/10.1093/cid/ciag466},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes
AU - Jacobo Pardo-Seco
AU - Carmen Rodriguez-Tenreiro-Sánchez
AU - Iago Giné-Vázquez
AU - Narmeen Mallah
AU - Susana Mirás-Carballal
AU - Marta Piñeiro-Sotelo
AU - Martín Cribeiro González
AU - Mónica Conde Pájaro
AU - Juan-Manuel González-Pérez
AU - Irene Rivero-Calle
AU - Xabier Bello
AU - Josefina L Razzini
AU - Antonio Salas
AU - Rebecca C Harris
AU - Matthew M Loiacono
AU - Robertus van Aalst
AU - Manel Farre
AU - Marine Dufournet
AU - Niklas Dyrby Johansen
AU - Daniel Modin
AU - Tor Biering-Sørensen
AU - Carmen Duran-Parrondo
AU - Federico Martinón-Torres
PY - 2026
DA - 2026/08/03
JO - Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
DO - 10.1093/cid/ciag466
UR - https://doi.org/10.1093/cid/ciag466
AB - The GALFLU trial showed a lower incidence of hospitalization among adults aged 65–79 years randomized to high-dose inactivated influenza vaccine (HD-IIV) vs standard-dose inactivated influenza vaccine (SD-IIV). This Bayesian re-analysis estimated >80% probability of benefit (relative vaccine effectiveness >10%) against influenza- or pneumonia-related hospitalization, supporting the benefit of HD-IIV over SD-IIV. Clinical Trials Registration. GALFLU ClinicalTrials.gov (NCT06141655); EudraCT (2023-506977-36-00).
SN - 1058-4838
SN - 1537-6591
ER -